Five Tibetan patent medicines orally for ischemic stroke: A systematic review and meta-analysis of randomized controlled trials

Tibetan Patent Medicines (TPMs) have unique advantages in the treatment of ischemic stroke (IS) with the features of multi-component, multi-channel, and multi-target. In China, five TPMs mainly consisting of precious medicinal materials such as gold, pearls, and agate are widely utilized to treat IS...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ethnopharmacology 2023-12, Vol.317, p.116671-116671, Article 116671
Main Authors: Zhang, Xu-Ran, Zang, Shu-Han, Zou, Hong-Xin, Zhu, Li-Hong, Sha, Ri-Na, Liu, Bo-Wen, Dong, Xing-Lu, Zhou, Li
Format: Article
Language:English
Subjects:
China
computer software
gold
hematocrit
Ischemic Stroke
Meta-analysis
stroke
Systematic review
Tibetan patent medicine
traditional medicine
Trial sequential analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c338t-87564748471d3828a3866397cba70f594d4626cfa29626659726055ea1fe08b93
container_end_page 116671
container_issue
container_start_page 116671
container_title Journal of ethnopharmacology
container_volume 317
creator Zhang, Xu-Ran
Zang, Shu-Han
Zou, Hong-Xin
Zhu, Li-Hong
Sha, Ri-Na
Liu, Bo-Wen
Dong, Xing-Lu
Zhou, Li
description Tibetan Patent Medicines (TPMs) have unique advantages in the treatment of ischemic stroke (IS) with the features of multi-component, multi-channel, and multi-target. In China, five TPMs mainly consisting of precious medicinal materials such as gold, pearls, and agate are widely utilized to treat IS and have achieved good results according to the current clinical practice. To systematically evaluate the efficacy and safety of the five TPMs orally in treating IS and provide a reference for future clinical application and research. We searched the following 24 databases up to December 11, 2022: China National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, Chinese Biomedical Database (CBM), PubMed, Embase, Web of Science, MEDLINE, Scopus, the Cochrane Library, ScienceDirect, etc. Comprehensive searches for randomized controlled trials (RCTs) of the five TPMs for IS were conducted. Outcome measures included clinical effective rate, neurological impairment score, activities of daily living (ADL), hematologic indices, and adverse events (AEs). The meta-regression, subgroup analyses, and sensitivity analyses were conducted to explore the sources of heterogeneity. We assessed the evidence grade of outcomes via the GRADE system. TSA software was used for trial sequential analyses of the clinical effective rate, neurological impairment score, and ADL. 17 RCTs (1603 patients) met our criteria. Compared with the control groups, the five TPMs showed greater improvement in clinical effective rate (RR = 1.23, 95% CI 1.17 to 1.29, P 
doi_str_mv 10.1016/j.jep.2023.116671
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153836068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378874123005391</els_id><sourcerecordid>2822378015</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-87564748471d3828a3866397cba70f594d4626cfa29626659726055ea1fe08b93</originalsourceid><addsrcrecordid>eNqFUU1P3DAUtBAItgs_gEvlI5cs_khsp5wQgrYSEhc4W17nRXibxIvtpVou_es8tNAjnObpaWakmSHklLMFZ1ydrxYrWC8EE3LBuVKa75EZN1pUutFyn8yY1KYyuuZH5FvOK8aY5jU7JEdSCyUl1zPy7yY8A70PSyhuomtXYCp0hC74MEGmMblh2NI-Jhqyf4QxeJpLin_gB72keZsLjK7gM8FzgL_UTR2qi6vc5IZtDujQ04TfOIYX6KiPE6qHAc-SghvyMTnoEeDkHefk4eb6_upXdXv38_fV5W3lpTQFQzSq1rWpNe-kEcZJo5RstV86zfqmrbtaCeV7J1pE1bQYkDUNON4DM8tWzsnZzned4tMGcrEjBoJhcBPETbaSN9JIxZT5kiqMEFgsQ8Wc8B3Vp5hzgt6uUxhd2lrO7NtEdmVxIvs2kd1NhJrv7_abJRb9X_GxCRIudgTAPrDVZLMPMHkcJYEvtovhE_tXGfehZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2822378015</pqid></control><display><type>article</type><title>Five Tibetan patent medicines orally for ischemic stroke: A systematic review and meta-analysis of randomized controlled trials</title><source>ScienceDirect Freedom Collection</source><creator>Zhang, Xu-Ran ; Zang, Shu-Han ; Zou, Hong-Xin ; Zhu, Li-Hong ; Sha, Ri-Na ; Liu, Bo-Wen ; Dong, Xing-Lu ; Zhou, Li</creator><creatorcontrib>Zhang, Xu-Ran ; Zang, Shu-Han ; Zou, Hong-Xin ; Zhu, Li-Hong ; Sha, Ri-Na ; Liu, Bo-Wen ; Dong, Xing-Lu ; Zhou, Li</creatorcontrib><description>Tibetan Patent Medicines (TPMs) have unique advantages in the treatment of ischemic stroke (IS) with the features of multi-component, multi-channel, and multi-target. In China, five TPMs mainly consisting of precious medicinal materials such as gold, pearls, and agate are widely utilized to treat IS and have achieved good results according to the current clinical practice. To systematically evaluate the efficacy and safety of the five TPMs orally in treating IS and provide a reference for future clinical application and research. We searched the following 24 databases up to December 11, 2022: China National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, Chinese Biomedical Database (CBM), PubMed, Embase, Web of Science, MEDLINE, Scopus, the Cochrane Library, ScienceDirect, etc. Comprehensive searches for randomized controlled trials (RCTs) of the five TPMs for IS were conducted. Outcome measures included clinical effective rate, neurological impairment score, activities of daily living (ADL), hematologic indices, and adverse events (AEs). The meta-regression, subgroup analyses, and sensitivity analyses were conducted to explore the sources of heterogeneity. We assessed the evidence grade of outcomes via the GRADE system. TSA software was used for trial sequential analyses of the clinical effective rate, neurological impairment score, and ADL. 17 RCTs (1603 patients) met our criteria. Compared with the control groups, the five TPMs showed greater improvement in clinical effective rate (RR = 1.23, 95% CI 1.17 to 1.29, P &lt; 0.00001), neurological impairment score (SMD = −1.71, 95% CI -2.31 to −1.10, P &lt; 0.00001), ADL (SMD = 1.97, 95% CI 1.26 to 2.68, P &lt; 0.00001), hematocrit (MD = −1.56, 95% CI -2.83 to −0.29, P = 0.02), and hypersensitive-c-reactive-protein (MD = −2.96, 95% CI -3.30 to −2.61, P &lt; 0.00001). AEs were reported in four RCTs and there was no statistical difference between groups (RD = −0.00, 95% CI -0.04 to 0.03, P = 0.82). The quality of evidence of the outcomes was rated as low to very low according to the GRADE system. The results of TSA provided firm evidence for the significant effect of the five TPMs on clinical effective rate, neurological impairment score, and ADL. This review showed that the five TPMs were beneficial in improving clinical effective rate, neurological impairment scores, and ADL. However, no definite conclusions for hematologic indices and AEs were drawn due to insufficient studies. Further high-quality clinical trials are required to confirm these findings. [Display omitted]</description><identifier>ISSN: 0378-8741</identifier><identifier>EISSN: 1872-7573</identifier><identifier>DOI: 10.1016/j.jep.2023.116671</identifier><identifier>PMID: 37263317</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>China ; computer software ; gold ; hematocrit ; Ischemic Stroke ; Meta-analysis ; stroke ; Systematic review ; Tibetan patent medicine ; traditional medicine ; Trial sequential analysis</subject><ispartof>Journal of ethnopharmacology, 2023-12, Vol.317, p.116671-116671, Article 116671</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c338t-87564748471d3828a3866397cba70f594d4626cfa29626659726055ea1fe08b93</cites><orcidid>0000-0001-9999-222X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37263317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xu-Ran</creatorcontrib><creatorcontrib>Zang, Shu-Han</creatorcontrib><creatorcontrib>Zou, Hong-Xin</creatorcontrib><creatorcontrib>Zhu, Li-Hong</creatorcontrib><creatorcontrib>Sha, Ri-Na</creatorcontrib><creatorcontrib>Liu, Bo-Wen</creatorcontrib><creatorcontrib>Dong, Xing-Lu</creatorcontrib><creatorcontrib>Zhou, Li</creatorcontrib><title>Five Tibetan patent medicines orally for ischemic stroke: A systematic review and meta-analysis of randomized controlled trials</title><title>Journal of ethnopharmacology</title><addtitle>J Ethnopharmacol</addtitle><description>Tibetan Patent Medicines (TPMs) have unique advantages in the treatment of ischemic stroke (IS) with the features of multi-component, multi-channel, and multi-target. In China, five TPMs mainly consisting of precious medicinal materials such as gold, pearls, and agate are widely utilized to treat IS and have achieved good results according to the current clinical practice. To systematically evaluate the efficacy and safety of the five TPMs orally in treating IS and provide a reference for future clinical application and research. We searched the following 24 databases up to December 11, 2022: China National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, Chinese Biomedical Database (CBM), PubMed, Embase, Web of Science, MEDLINE, Scopus, the Cochrane Library, ScienceDirect, etc. Comprehensive searches for randomized controlled trials (RCTs) of the five TPMs for IS were conducted. Outcome measures included clinical effective rate, neurological impairment score, activities of daily living (ADL), hematologic indices, and adverse events (AEs). The meta-regression, subgroup analyses, and sensitivity analyses were conducted to explore the sources of heterogeneity. We assessed the evidence grade of outcomes via the GRADE system. TSA software was used for trial sequential analyses of the clinical effective rate, neurological impairment score, and ADL. 17 RCTs (1603 patients) met our criteria. Compared with the control groups, the five TPMs showed greater improvement in clinical effective rate (RR = 1.23, 95% CI 1.17 to 1.29, P &lt; 0.00001), neurological impairment score (SMD = −1.71, 95% CI -2.31 to −1.10, P &lt; 0.00001), ADL (SMD = 1.97, 95% CI 1.26 to 2.68, P &lt; 0.00001), hematocrit (MD = −1.56, 95% CI -2.83 to −0.29, P = 0.02), and hypersensitive-c-reactive-protein (MD = −2.96, 95% CI -3.30 to −2.61, P &lt; 0.00001). AEs were reported in four RCTs and there was no statistical difference between groups (RD = −0.00, 95% CI -0.04 to 0.03, P = 0.82). The quality of evidence of the outcomes was rated as low to very low according to the GRADE system. The results of TSA provided firm evidence for the significant effect of the five TPMs on clinical effective rate, neurological impairment score, and ADL. This review showed that the five TPMs were beneficial in improving clinical effective rate, neurological impairment scores, and ADL. However, no definite conclusions for hematologic indices and AEs were drawn due to insufficient studies. Further high-quality clinical trials are required to confirm these findings. [Display omitted]</description><subject>China</subject><subject>computer software</subject><subject>gold</subject><subject>hematocrit</subject><subject>Ischemic Stroke</subject><subject>Meta-analysis</subject><subject>stroke</subject><subject>Systematic review</subject><subject>Tibetan patent medicine</subject><subject>traditional medicine</subject><subject>Trial sequential analysis</subject><issn>0378-8741</issn><issn>1872-7573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFUU1P3DAUtBAItgs_gEvlI5cs_khsp5wQgrYSEhc4W17nRXibxIvtpVou_es8tNAjnObpaWakmSHklLMFZ1ydrxYrWC8EE3LBuVKa75EZN1pUutFyn8yY1KYyuuZH5FvOK8aY5jU7JEdSCyUl1zPy7yY8A70PSyhuomtXYCp0hC74MEGmMblh2NI-Jhqyf4QxeJpLin_gB72keZsLjK7gM8FzgL_UTR2qi6vc5IZtDujQ04TfOIYX6KiPE6qHAc-SghvyMTnoEeDkHefk4eb6_upXdXv38_fV5W3lpTQFQzSq1rWpNe-kEcZJo5RstV86zfqmrbtaCeV7J1pE1bQYkDUNON4DM8tWzsnZzned4tMGcrEjBoJhcBPETbaSN9JIxZT5kiqMEFgsQ8Wc8B3Vp5hzgt6uUxhd2lrO7NtEdmVxIvs2kd1NhJrv7_abJRb9X_GxCRIudgTAPrDVZLMPMHkcJYEvtovhE_tXGfehZA</recordid><startdate>20231205</startdate><enddate>20231205</enddate><creator>Zhang, Xu-Ran</creator><creator>Zang, Shu-Han</creator><creator>Zou, Hong-Xin</creator><creator>Zhu, Li-Hong</creator><creator>Sha, Ri-Na</creator><creator>Liu, Bo-Wen</creator><creator>Dong, Xing-Lu</creator><creator>Zhou, Li</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0001-9999-222X</orcidid></search><sort><creationdate>20231205</creationdate><title>Five Tibetan patent medicines orally for ischemic stroke: A systematic review and meta-analysis of randomized controlled trials</title><author>Zhang, Xu-Ran ; Zang, Shu-Han ; Zou, Hong-Xin ; Zhu, Li-Hong ; Sha, Ri-Na ; Liu, Bo-Wen ; Dong, Xing-Lu ; Zhou, Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-87564748471d3828a3866397cba70f594d4626cfa29626659726055ea1fe08b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>China</topic><topic>computer software</topic><topic>gold</topic><topic>hematocrit</topic><topic>Ischemic Stroke</topic><topic>Meta-analysis</topic><topic>stroke</topic><topic>Systematic review</topic><topic>Tibetan patent medicine</topic><topic>traditional medicine</topic><topic>Trial sequential analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xu-Ran</creatorcontrib><creatorcontrib>Zang, Shu-Han</creatorcontrib><creatorcontrib>Zou, Hong-Xin</creatorcontrib><creatorcontrib>Zhu, Li-Hong</creatorcontrib><creatorcontrib>Sha, Ri-Na</creatorcontrib><creatorcontrib>Liu, Bo-Wen</creatorcontrib><creatorcontrib>Dong, Xing-Lu</creatorcontrib><creatorcontrib>Zhou, Li</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of ethnopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xu-Ran</au><au>Zang, Shu-Han</au><au>Zou, Hong-Xin</au><au>Zhu, Li-Hong</au><au>Sha, Ri-Na</au><au>Liu, Bo-Wen</au><au>Dong, Xing-Lu</au><au>Zhou, Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five Tibetan patent medicines orally for ischemic stroke: A systematic review and meta-analysis of randomized controlled trials</atitle><jtitle>Journal of ethnopharmacology</jtitle><addtitle>J Ethnopharmacol</addtitle><date>2023-12-05</date><risdate>2023</risdate><volume>317</volume><spage>116671</spage><epage>116671</epage><pages>116671-116671</pages><artnum>116671</artnum><issn>0378-8741</issn><eissn>1872-7573</eissn><abstract>Tibetan Patent Medicines (TPMs) have unique advantages in the treatment of ischemic stroke (IS) with the features of multi-component, multi-channel, and multi-target. In China, five TPMs mainly consisting of precious medicinal materials such as gold, pearls, and agate are widely utilized to treat IS and have achieved good results according to the current clinical practice. To systematically evaluate the efficacy and safety of the five TPMs orally in treating IS and provide a reference for future clinical application and research. We searched the following 24 databases up to December 11, 2022: China National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, Chinese Biomedical Database (CBM), PubMed, Embase, Web of Science, MEDLINE, Scopus, the Cochrane Library, ScienceDirect, etc. Comprehensive searches for randomized controlled trials (RCTs) of the five TPMs for IS were conducted. Outcome measures included clinical effective rate, neurological impairment score, activities of daily living (ADL), hematologic indices, and adverse events (AEs). The meta-regression, subgroup analyses, and sensitivity analyses were conducted to explore the sources of heterogeneity. We assessed the evidence grade of outcomes via the GRADE system. TSA software was used for trial sequential analyses of the clinical effective rate, neurological impairment score, and ADL. 17 RCTs (1603 patients) met our criteria. Compared with the control groups, the five TPMs showed greater improvement in clinical effective rate (RR = 1.23, 95% CI 1.17 to 1.29, P &lt; 0.00001), neurological impairment score (SMD = −1.71, 95% CI -2.31 to −1.10, P &lt; 0.00001), ADL (SMD = 1.97, 95% CI 1.26 to 2.68, P &lt; 0.00001), hematocrit (MD = −1.56, 95% CI -2.83 to −0.29, P = 0.02), and hypersensitive-c-reactive-protein (MD = −2.96, 95% CI -3.30 to −2.61, P &lt; 0.00001). AEs were reported in four RCTs and there was no statistical difference between groups (RD = −0.00, 95% CI -0.04 to 0.03, P = 0.82). The quality of evidence of the outcomes was rated as low to very low according to the GRADE system. The results of TSA provided firm evidence for the significant effect of the five TPMs on clinical effective rate, neurological impairment score, and ADL. This review showed that the five TPMs were beneficial in improving clinical effective rate, neurological impairment scores, and ADL. However, no definite conclusions for hematologic indices and AEs were drawn due to insufficient studies. Further high-quality clinical trials are required to confirm these findings. [Display omitted]</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>37263317</pmid><doi>10.1016/j.jep.2023.116671</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9999-222X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0378-8741
ispartof Journal of ethnopharmacology, 2023-12, Vol.317, p.116671-116671, Article 116671
issn 0378-8741
1872-7573
language eng
recordid cdi_proquest_miscellaneous_3153836068
source ScienceDirect Freedom Collection
subjects China
computer software
gold
hematocrit
Ischemic Stroke
Meta-analysis
stroke
Systematic review
Tibetan patent medicine
traditional medicine
Trial sequential analysis
title Five Tibetan patent medicines orally for ischemic stroke: A systematic review and meta-analysis of randomized controlled trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A34%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five%20Tibetan%20patent%20medicines%20orally%20for%20ischemic%20stroke:%20A%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials&rft.jtitle=Journal%20of%20ethnopharmacology&rft.au=Zhang,%20Xu-Ran&rft.date=2023-12-05&rft.volume=317&rft.spage=116671&rft.epage=116671&rft.pages=116671-116671&rft.artnum=116671&rft.issn=0378-8741&rft.eissn=1872-7573&rft_id=info:doi/10.1016/j.jep.2023.116671&rft_dat=%3Cproquest_cross%3E2822378015%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c338t-87564748471d3828a3866397cba70f594d4626cfa29626659726055ea1fe08b93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2822378015&rft_id=info:pmid/37263317&rfr_iscdi=true